February 2026 Research Update

What this month adds

This month highlighted that relapsing polychondritis can overlap with health issues that show up outside the ears, nose, and joints, especially in the airway and in conditions that share inflammation. Two larger database or registry studies pointed to higher risks in specific groups, while a case report showed how new digestive symptoms during a flare or medication change can uncover a second inflammatory disease. [1] [2] [3]

In a large electronic health record analysis of women with autoimmune diseases (including relapsing polychondritis), estrogen-containing hormone replacement therapy was linked to a higher rate of autoimmune-related vocal fold lesions, which are inflammatory lesions affecting the voice box. The reported difference was 1.65 times higher risk in those exposed to estrogen-containing HRT compared with those not exposed. This strengthens the idea that hormone pathways may influence inflammation in the larynx, but it does not show that estrogen causes these lesions. [1]

A separate international registry study looked at VEXAS syndrome (a different inflammatory condition that can include relapsing polychondritis-like features) and found a higher overall cancer risk compared with other inflammatory disease controls. Within the VEXAS group, having relapsing polychondritis was one of the factors linked to higher cancer risk, along with a specific UBA1 mutation and higher inflammation markers. For patients, this mainly adds context that some relapsing polychondritis presentations may sit within broader inflammatory syndromes that carry different long-term risks. [2]

One case report described a person with relapsing polychondritis whose new abdominal symptoms during steroid tapering led to a diagnosis of Crohn's disease. After treatment for Crohn's disease and immune suppression, both digestive symptoms and joint pain improved by 3 months. As a single-patient report, it cannot show how common this overlap is, but it reinforces that new symptom patterns can sometimes reflect a second inflammatory condition rather than relapsing polychondritis alone. [3]

How to think about this

For patients and caregivers, the main point is that February's studies added more detail about which subgroups might have added risks that are not limited to cartilage inflammation. The hormone-related voice box finding and the VEXAS cancer-risk finding come from observational data, so they help map patterns but cannot prove cause and effect. These results may matter most for understanding why some people develop prominent throat or whole-body issues, and why clinicians sometimes consider related diagnoses like VEXAS when the overall picture does not fit typical relapsing polychondritis. [1] [2]

Important uncertainties remain, including how often these issues apply specifically to people with relapsing polychondritis, since the largest studies grouped multiple autoimmune diseases or focused on VEXAS rather than relapsing polychondritis alone. Still, the studies help clarify that relapsing polychondritis can sit in a wider inflammation landscape, where voice symptoms, digestive symptoms, or broader syndrome features may be relevant clues. [1] [2] [3]

What this month adds

This month included a safety-focused case report showing a rare but important reaction to dapsone in a person with relapsing polychondritis. The report ties together a recognizable pattern of low pulse-oximeter readings despite normal oxygen levels, plus anemia from red blood cell damage, which improved after stopping the drug and giving an antidote treatment. The key addition is awareness of a specific side effect pattern rather than a new treatment benefit. [4]

In the reported patient, after about 3 months on dapsone, testing confirmed methemoglobinemia (a change in hemoglobin that reduces its ability to carry oxygen) and signs of oxidant hemolysis (red blood cell injury). The methemoglobin level reported was 15%, and it rapidly decreased after methylene blue, with continued improvement after dapsone was discontinued. Because this is a single case, it cannot tell how often this happens, but it clearly documents that it can occur in relapsing polychondritis care. [4]

How to think about this

For patients, this is mainly an early safety signal rather than a change in what is known to work for relapsing polychondritis. It matters now in the sense that it describes a specific, test-confirmable complication linked to dapsone that improved when recognized and treated in this one person. What remains uncertain is how common this reaction is among people with relapsing polychondritis and which patients are most at risk. [4]